NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 54 min ago

International Collaborations: Policies, Processes, and Partnerships NIH Virtual Event on November 9, 2022

Mon, 2022-10-24 03:46
Notice NOT-OD-23-009 from the NIH Guide for Grants and Contracts

NIH Operates Under a Continuing Resolution

Mon, 2022-10-24 03:38
Notice NOT-OD-23-005 from the NIH Guide for Grants and Contracts

Utilizing Telomere Status to Reveal Molecular Mechanisms Underlying Susceptibility and Resiliency in Response to Environmental Exposures (R01 Clinical Trial Not Allowed)

Fri, 2022-10-21 13:47
Funding Opportunity RFA-ES-22-007 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to solicit applications that further examine and characterize molecular underpinnings surrounding telomere status and accompanying biological pathways in response to environmental insults. Specifically, the intent is to further stimulate the field on how general telomere maintenance modulates downstream biological pathway(s) leading to cellular and organismal dysfunction. It is anticipated that proposed studies examining exposure affects at telomeric regions can actually potentiate early onset of age-related diseases. This FOA ultimately seeks to identify key mechanistic insights into telomere dynamics and how this could better dissect the interplay between environmental exposures at this vulnerable site contribute to disease (e.g., cancer, CVD, and other age-related outcomes, such as neurodegeneration).

Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)

Fri, 2022-10-21 13:40
Funding Opportunity RFA-DK-22-039 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental biological mechanisms underlying HIV-associated comorbidities, co-infections, and complications relevant to the mission of the NIDDK and advance progress toward preventing or alleviating them.

Notice of NICHD Participation in PAR-22-243, "Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)"

Fri, 2022-10-21 13:25
Notice NOT-HD-22-051 from the NIH Guide for Grants and Contracts

Notice of NICHD Participation in PAR-22-242, "Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)"

Fri, 2022-10-21 13:15
Notice NOT-HD-22-050 from the NIH Guide for Grants and Contracts

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)

Fri, 2022-10-21 11:42
Funding Opportunity PAR-23-021 from the NIH Guide for Grants and Contracts. Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.

Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)

Thu, 2022-10-20 02:44
Funding Opportunity RFA-DA-24-007 from the NIH Guide for Grants and Contracts. oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. In recent years, there have been significant advances in methods and technologies for the identification of novel targets, mechanisms, and pathways of interest to substance use disorders and in identification of probes and optimized compounds for developing novel therapeutic agents. This FOA is to enable investigators with knowledge in the emerging chemical, pharmacological, and drug discovery technologies to pursue innovative and transformative research on chemical and pharmacological aspects of substance use disorders.

Pages